Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia, Schizoaffective Disorder
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia
- Trial name
- NCT03495024
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Schizophrenia, Psychotic Disorders
Efficacy of Metacognitive Training Single Modules: Jumping to Conclusions and To Empathize...
The purpose of this study is to determine whether modules of Metacognitive Training: Jumping to Conclusions and To empathize... are effective in the treatment of patients with schizophrenia.
- Trial name
- NCT02748486
- Testing
- Metacognitive Training Jumping to Conclusion, Group discussion, Metacognitive Training To Empathize
- Volunteers
- 38 people
- Sponsor
- University of Warsaw
Schizophrenia Spectrum & Other Psychotic Disorders
PACT for Individuals With Serious Mental Illness
People with serious mental illness have difficulty making good use of primary care, and die, on average, years earlier than others in the population.
- Trial name
- SMI-PACT (NCT01668355)
- Testing
- Patient Aligned Care Team (PACT)
- Where
- 3 sites in United States
- Volunteers
- 331 people
- Sponsor
- VA Office of Research and Development
Bipolar I Disorder, Schizophrenia
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
This is a single-center open-label study to be conducted in the United States in subjects with bipolar I disorder or schizophrenia.
- Trial name
- NCT04127058
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
Lurasidone Non-Interventional Study in Schizophrenia Patients
The study is a multicentric, national, non-interventional, prospective, single arm study. The main goal of this study is to gather information about the effects, in a real-life setting, of lurasidone treatment on patient's…
- Trial name
- NCT06527885
- Testing
- Lurasidone
- Where
- 3 sites in Italy
- Volunteers
- 61 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Schizophrenia Disorder, Metabolic Syndrome
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
Patients with schizophrenia on second-generation antipsychotics have a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options.
- Conditions
- Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk
- Trial name
- NCT07770282
- Testing
- Semaglutide + TAU
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia
Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119
This study will consist of 2 parts: Part Ⅰ-in healthy adult subjects, Part Ⅱ-in adult patients with schizophrenia
- Trial name
- NCT06504290
- Testing
- VV119 （in healthy adult subjects）, VV119(in adult patients with schizophrenia)
- Where
- 4 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
22q11 Deletion Syndrome
Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.
The purpose of the present trial is to investigate the effects of omega-3 PUFAs in individuals aged 12-26 years with 22q11DS at ultra-high risk for developing a first episode of psychosis.
- Trial name
- NCT02070211
- Testing
- omega-3 PUFAs, Standard care
- Where
- Holy See
- Volunteers
- 80 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Schizophrenia, Psychotic Disorders
Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection
The purpose of this study is to assess the usefulness of the Risperdal® Consta® Treatment Guidebook in helping the doctor switch the adult patient from taking risperidone tablets daily by mouth to taking long-acting risperidone…
- Trial name
- NCT00236548
- Testing
- risperidone
- Volunteers
- 1 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia
The TURNS is a National Institute of Mental Health (NIMH) funded contract for the evaluation of new compounds for the treatment of cognitive impairments in schizophrenia (HHSN 27820044 1003C; P.I.: Steve Marder, M.D.).
- Trial name
- NCT00425815
- Testing
- Org 24448
- Where
- 8 sites in United States
- Sponsor
- University of California, Los Angeles
Schizophrenia
Quality of Life in Schizophrenic Patients
This is a non-interventional study evaluating quality of life in schizophrenic patients treated with atypical antipsychotics, in the ambulatory setting. This is a 9-month, observational, multicentric prospective study.
- Trial name
- Quality (NCT00597168)
- Where
- 45 sites in Belgium
- Volunteers
- 124 people
- Sponsor
- AstraZeneca
Alcoholism, Schizophrenia
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
This placebo-controlled study is designed to evaluate the efficacy of glycine, an agonist of the glycine-B co-agonist site of the NMDA receptor, on alcohol consumption and craving as well as negative symptoms in schizophrenia.
- Trial name
- NCT00338598
- Testing
- Glycine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Schizophrenia, Psychotic Disorders
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine…
- Trial name
- NCT00216476
- Testing
- Aripiprazole, Risperidone Long Acting Injectable (LAI), Quetiapine
- Where
- 96 sites in Austria, Bulgaria and 22 more
- Volunteers
- 753 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia
Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)
Treatment with conventional antipsychotics such as haloperidol has little effect or may sometimes even worsen negative symptoms (such as blunted affect, emotional withdrawal, and poor rapport) of schizophrenia.
- Trial name
- NCT00212836
- Testing
- asenapine, olanzapine
- Volunteers
- 481 people
- Sponsor
- Organon and Co
Schizophrenia
The Effect of an Individual Empowerment Program Provided to Relatives of Schizophrenia Patients
Psychoeducation provided to family members caring for individuals with schizophrenia. Has been found to positively impact caregivers' psychological well-being and the effective management of schizophrenia patients.However…
- Trial name
- NCT07173192
- Testing
- Individual empowerment program
- Where
- Turkey (Türkiye)
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Istanbul Arel University
Schizophrenia
A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia
To investigate the efficacy and safety of OPC-34712 in comparison with placebo in patients with schizophrenia.
- Trial name
- NCT01451164
- Testing
- OPC-34712
- Where
- Japan
- Volunteers
- 459 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia
The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults.
- Trial name
- NCT00101634
- Testing
- Paliperidone palmitate
- Volunteers
- 518 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone
The purpose of this study is to evaluate medication satisfaction after at least 4 weeks of paliperidone ER (extended-release), an antipsychotic, treatment in patients with schizophrenia who were previously taking either 4 or 6 mg…
- Trial name
- NCT00535132
- Testing
- Oral Risperidone, Paliperidone ER
- Where
- 40 sites in United States, Argentina and 4 more
- Volunteers
- 201 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Inhibition (Psychology), Schizophrenia
Prepulse Inhibition (PPI) of Startle Reflex in Schizophrenia Patients Related to Type of Treatment and Illness Duration
PPI is an objective measure to assess pre-attentive processes that have already been tested before in the case of schizophrenia.
- Conditions
- Inhibition (Psychology), Schizophrenia, Medication Adherence
- Trial name
- NCT02484521
- Testing
- PPI monitoring device protocol, Questionnaires
- Where
- Israel
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- HaEmek Medical Center, Israel
Schizophrenia
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
The purpose of this study is to demonstrate the effectiveness of paliperidone palmitate in patients with Schizophrenia.
- Trial name
- NCT00589914
- Testing
- RISPERDAL CONSTA, Paliperidone palmitate
- Where
- 82 sites in United States, Austria and 12 more
- Volunteers
- 1,221 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.